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1. Introduction 
Down syndrome (DS) is the most common chromosomal abnormality, with an incidence of 
approximately 1 per 500 to 800 live births (Egan et al., 2004). DS is associated with an 
impairment of cognitive ability and physical growth, and a particular set of facial 
characteristics. Moreover, about 50% of all people with DS suffer from a congenital heart 
defect and DS patients are more prone to develop serious illnesses such as Alzheimer’s 
disease, leukaemia and epilepsy. These factors all contribute to a shorter life expectancy.  
For decades, people developed methods to prenatally diagnose DS. In this chapter an 
overview is given of non-invasive screening methods for DS. The research described in this 
chapter was performed at the Dutch National Institute for Public Health and the 
Environment (RIVM). The RIVM acts as the reference laboratory for DS screening in the 
Netherlands and processes over 10,000 first-trimester combined tests per year. The RIVM 
therefore possesses an extensive collection of sera of pregnant women carrying a foetus with 
DS and other congenital abnormalities. For our scientific studies, serum samples from this 
large database were used. The aim of our research was to identify new biochemical 
screening markers using proteomics techniques to improve the performance of the current 
DS screening. 
2. Down syndrome screening 
2.1 A historical perspective of Down syndrome 
An accurate phenotypic description of Down syndrome (DS) was published by John 
Langdon Down in 1866 (Down, 1866). Following descriptions of Esquirol and Séguin 
(Esquirol, 1838, Séguin, 1846), who wrote about phenotypic differences between mentally 
retarded humans, Down was the first to make the distinction between the phenotype which 
is now called DS and other disorders. He made this distinction based on an ethnic 
classification in which he discerned four types; the Ethiopian type, the Malay type, the 
American type and the Mongolian type (Down, 1866). Down noticed that the ‘mongolism’ 
occurred in more that 10% of all mentally retarded children and that it was always 
congenital. 
At the end of the 19th century, the principle of inheritance was explained by the discovery of 
chromosomes in living organisms. In 1909, Morgan and colleagues began to study the 
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chromosomes of Drosophila (fruit flies), which were very suitable for genetic studies because 
they bred quickly and only have four chromosomes. During their experiments it was, 
among others, discovered that occasionally Drosophila possessed three sex chromosomes 
instead of two showing a pattern of XXY or XYY, an abnormality which they called ‘trisomy’ 
(Morgan et al., 1925, Morgan et al., 1915). Since this trisomy occurred when two copies of a 
chromosome failed to disjoin properly, it was described as non-disjunction.  
Somewhat later, in the 1930s, two researchers independently linked non-disjunction to DS. 
Waardenburg stated that, due to the extended clinical features of humans with DS, the 
syndrome might very well be caused by something as complicated as a chromosomal 
disorder (Waardenburg, 1932). Bleyer proposed that DS occurs with fertilization or has 
already occurred before, during the period of maturation of the ovum or spermatozoon 
(Bleyer, 1934). Therefore, he thought that a chromosomal abnormality such as non-
disjunction was most likely to cause DS. 
Finally, in 1959, a few years after it had been established that human tissues normally 
contain 46 chromosomes, Lejeune and Jacobs independently discovered the presence of an 
extra chromosome in children with DS (Jacobs et al., 1959, Lejeune et al., 1959). Lejeune 
suggested, principally based on the Drosophila research, that the presence of an extra 
chromosome could well be explained in terms of non-disjunction. As individual 
chromosomes were identified, it appeared that the extra chromosome in DS was always the 
21st chromosome. Therefore, DS was since then referred to as trisomy 21.  
2.2 Prenatal screening for Down syndrome 
The discovery of a trisomy of chromosome 21 as the underlying cause for DS and the 
possibility to perform a chromosome analysis on amniotic fluid allowed for the prenatal 
diagnosis of DS (Valenti et al., 1968).  
In 1966 the first chromosome analysis of amniotic fluid was performed (Steele and Breg, 
1966). This development allowed for the prenatal detection of DS, which was first achieved 
in 1968 (Valenti et al., 1968). The relationship between the risk of having a child with DS and 
advanced maternal age had been known for a long time (Penrose, 1933, Shuttleworth, 1909). 
A statistical estimation of this relationship is shown in figure 1. Because of an increased risk 
of DS, in many countries women above a certain age (usually above 35-38 years) were 
offered prenatal diagnosis by means of amniocentesis.  
In 1972 it was discovered that very high levels of alpha fetoprotein (AFP) were present in 
the amniotic fluid of women carrying a child with a neural tube defect (NTD) (Brock and 
Sutcliffe, 1972). Two years later the association between high AFP levels and NTD was also 
seen in second trimester maternal serum samples (Brock et al., 1974, Wald et al., 1974), 
allowing for a non-invasive screening method for NTD (Wald et al., 1977). Again a few years 
later, in 1984, it was found that, in contrast to the elevated AFP levels in NTD pregnancies, 
decreased maternal serum levels of AFP in the second trimester of pregnancy could be 
linked to DS (Cuckle et al., 1984, Merkatz et al., 1984). This meant that prenatal screening for 
NTD could be extended with the screening for DS. This way, women of advanced maternal 
age could now be offered a screening test before opting for an invasive amniocentesis that 
bears a certain risk of miscarriage (Eddleman et al., 2006, Odibo et al., 2008). 
The discovery of AFP as a second trimester screening marker for DS triggered researchers to 
look for other potential screening markers to even further improve the prenatal detection by 
screening. In 1987, two new screening markers were presented. Maternal serum levels of 
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human chorion gonadotropin (hCG) were shown to be, on average, higher in DS 
pregnancies (Bogart et al., 1987) while levels of unconjugated estriol (uE3) were mostly 
decreased in DS (Canick et al., 1988). A year later, Wald and colleagues reported on a new 
method of screening using the three biochemical markers (AFP, hCG and uE3) together with 
maternal age as parameters in a single test (Wald et al., 1988). This test became known as the 
‘triple test’. With the triple test 60% of all DS cases could be prenatally detected at a 5% false 
positive rate (FPR) (Wald et al., 1988), which was a significant improvement compared to 
the detection of the previous screening method based on maternal age and AFP only 
(Cuckle et al., 1984). The triple test became increasingly popular as a screening test for DS 
and started to be carried out routinely in several countries. The most optimal cut-off risk for 
the screening was calculated to be 1 in 250 (Baumgarten, 1985). During the early 1990s, the 
triple test was adjusted by the replacement of hCG with the free beta subunit of hCG (fβ-
hCG) (Macri et al., 1990, Ryall et al., 1992). Moreover, in 1996, inhibin-A was found to 
contribute to the current triple test (Wald et al., 1996) and with the addition of inhibin-A the 
‘quadruple test’ was conceived.  
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Fig. 1. The relationship between maternal age and the risk of having a child with Down 
syndrome based on data from Cuckle et al. (Cuckle et al., 1987). 
In the meantime the focus of prenatal screening for DS shifted more towards the first 
trimester of pregnancy. This development was in part due to the applicability of chorionic 
villus sampling, a technique that allows for karyotyping already in the first trimester. Thus, 
it became possible to detect DS earlier in pregnancy, what subsequently allowed for earlier 
termination of pregnancy. On the other hand, first trimester screening would not include 
screening for NTD. However, advanced ultrasound techniques were developed promising 
high detection rates for NTD in the second trimester.    
Except for fβ-hCG (Spencer et al., 1992), the parameters in the current triple test did not 
perform well in the distinction between DS and euploid pregnancies in the first trimester. 
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So, to come up with a proper test, new first trimester screening markers were necessary.  In 
1991, it was found that maternal serum pregnancy associated plasma protein-A (PAPP-A) 
was reduced about 50% in DS pregnancies (Brambati et al., 1993). Besides PAPP-A, more 
potential markers were studied (e.g. SP1 (Kornman et al., 1998) and CA125 (Van Lith et al., 
1993)), but none of those turned out to be worth adding to the screening test. The search for 
DS screening markers was not limited to biochemical markers; an enlarged nuchal 
translucency (NT) on a first trimester ultrasound scan also turned out to be predictive for DS 
(Nicolaides et al., 1992, Pandya et al., 1994). Combining these three screening markers (fβ-
hCG, PAPP-A and NT) with maternal age, using a risk calculation method similar to that of 
the triple test, originated the ‘first trimester combined test’ (Wald and Hackshaw, 1997). 
Over the years, numerous studies have been published showing that with the first trimester 
combined test approximately 85-90% of all DS cases could be detected at a 5% FPR (Jaques et 
al., 2007, Nicolaides et al., 2005, Spencer and Nicolaides, 2003, Valinen et al., 2007, 
Wojdemann et al., 2005). 
Under strict guidelines issued by the Dutch Centre for Population Research the first-
trimester screening policy for DS was fully implemented in the Netherlands as of January 1, 
2007. Since then, all pregnant women are offered such prenatal screening for DS, but the 
uptake of the test is only 23% (Schielen et al., 2008), which is rather low as compared to 
other countries. The detection rate (DR) of DS screening in the Netherlands is currently 76% 
(Wortelboer et al., 2009a).  
3. Proteomics techniques to identify new screening markers for Down 
syndrome 
The development of methods for DS screening has so far mainly been based on 
coincidences. The screening really is a spin-off of the neural tube defect (NTD) screening, 
and the most effective markers were discovered by fishing expeditions, not by thorough 
analysis of the causal relationship of genes on chromosome 21 and foetal or placental 
proteins that are likely to cause an excess or shortage in maternal serum as a result.  
A proteome is the entire complement of proteins including the modifications made to a 
particular set of proteins, produced by an organism or system. Proteomics is the field of 
research that aims at examination of the proteome in a certain tissue, cell type or body fluid 
at a certain time point. A plethora of emerging methodological tools allows for the study of 
proteins, e.g. their quantity, cellular location and post-translational modifications. 
Understanding the proteome, the structure and function of each protein, and the 
complexities of protein-interactions during a DS pregnancy may help in the search for 
additional biomarkers for current first-trimester DS screening. 
Our proteomics research consists of three phases (figure 2): i) the discovery of new 
biomarkers for first-trimester DS screening, ii) the feasibility and validation of proteomics 
techniques to analyze multiple markers simultaneously, iii) the implementation of a cost-
effective assay for large-scale screening programmes. 
The presence of an extra chromosome in DS not only leads to anomalies of the foetus, but 
also of the placenta. In human trophoblast cells, the excess of oxygen radicals produced 
during oxygen metabolism are eliminated by natural antioxidants and superoxide 
dismutase (SOD). The gene responsible for this reaction is Zn-SOD and is encoded by 
chromosome 21. SOD expression and protein levels and activity are significantly higher 
(about 50%) in trophoblast cells from DS placentas (Pidoux et al., 2004). Over-expression of  
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Fig. 2. Three phases of proteomics research for DS screening described in this chapter. 
SOD hampers normal trophoblast formation; DS trophoblast cells cannot fully compensate 
for the reduced oxidative stress resulting in placental abnormalities. DS placentas show 
signs of impaired differentiation, aggregation and fusion of their trophoblast cells. This 
could lead to undervascularisation, hypotrophy and cell apoptosis of the placenta already in 
the first trimester of pregnancy (Koster et al., 2010a). As a result of these pathological 
changes deregulation and/or differential expression occurs for proteins, e.g. cytokines and 
growth factors, involved in implantation and placental development (Bromage et al., 2000, 
Vesce et al., 2002). This may cause an increased or decreased placental expression of 
biological markers (hormones and proteins). PAPP-A and fβ-hCG, currently used as DS 
screening markers in the first-trimester combined test, are such markers. PAPP-A is a 
protein which is thought to be an important regulator of IGF bioavailability and cell growth 
(Giudice et al., 2002) and fβ-hCG is a subunit of total hCG, which is the most important 
hormone involved in early pregnancy and provides for the maintenance of the corpus 
luteum and of pregnancy (Stenman et al., 2006). Based on this knowledge the differential 
expression of other placenta derived proteins, given that it is traceable in maternal blood, 
could be used in the search for new screening markers. 
In the discovery phase of our research, an extensive review of the literature was carried out 
to study normal placental development and function during early pregnancy (Koster et al., 
2010a). Using this knowledge, candidate biomarkers were proposed which may be useful in 
screening for DS. Current screening markers for DS indeed mainly originate from the 
placenta, but can also be traced to the foetal liver, e.g. alpha-fetoprotein (AFP). It is therefore 
hypothesized that new screening markers may also originate from these tissues. However, a 
prerequisite of a good screening marker is that concentrations of a protein are detectable in 
maternal serum. The amount of information on genes and proteins in public databases is 
increasing rapidly, which allows for a bioinformatics approach that involves automated 
collection and combination of information from biological databases, known as data mining. 
A bioinformatics approach was developed to use data from the literature on genes and 
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protein expression and data-textmining tools. This way, a list of 49 potential DS screening 
markers was generated (Pennings et al., 2009). The list included three biomarkers that are 
already used for DS screening (AFP, fβ-hCG and PAPP-A) and several others, among which 
proteins that have been examined as potential biomarkers before. Furthermore, there was a 
large overlap between the proposed screening markers based on the literature review and 
the data mining (table 1). 
Biomarker discovery research within our proteomics project also included the use of mouse-
models for biomarker identification (Pennings et al, 2011). Breeding healthy female mice and 
male transgenic mice with DS (type Ts(16C-tel)1Cje; The Jackson Laboratory, Bar Harbor, 
ME, USA) produces healthy females pregnant with, on average, 50% DS embryos. Blood 
was drawn from the pregnant mice during the first trimester, for the identification of 
potential screening markers in maternal serum. Then, the pregnancy was terminated and 
the placenta and foetal organs were collected. Gene profiles were analyzed using a whole 
genome microarray approach to study the difference between DS and unaffected siblings. 
Genes that showed over- or underexpression in the placentas of DS foetuses were C2cd2, 
Dyrk1a, Ifnar2, Morc3, Sfrs15, Sod1, Tmprss2, Fgfbp3. Ongoing research focuses on the 
serum detectability of these gene products, and their potential as a biomarker for DS 
screening in human serum. 
We continued our search for potential screening markers by examining the proteins that 
have been suggested as first-trimester screening markers for aneuploidies in international 
studies. One of those markers is placental protein 13 (PP13) which plays an important role in 
the implantation and modelling of foetal-maternal blood spaces between placenta and 
endometrium. PP13 is produced by the placenta, which is hampered in trisomic 
pregnancies, and was found to be decreased in DS pregnancies and, to greater extent, in 
trisomy 18 and 13 pregnancies (Akolekar et al., 2010, Koster et al., 2009b). Serum 
concentrations of a disintegrin and metalloprotease 12 (ADAM12) and placental growth 
factor (PlGF) are also decreased in DS pregnancies (Wortelboer et al., 2009b, Zaragoza et al., 
2009). Total hCG (thCG), which is a screening marker for DS in the second trimester of 
pregnancy, is increased in maternal serum from first-trimester DS pregnancies (Hallahan et 
al., 2000). However, when these four markers were added to the current first-trimester 
combined test algorithm the DR increased by only 3% (table 2a) (Koster et al., 2010d).  
These studies show that the predictive power of maternal serum markers is not constant 
during the first trimester. For three markers (PAPP-A, ADAM12 and PP13) the difference 
between DS and unaffected pregnancies is more distinct early in the first trimester (before 11 
weeks), while for the remaining markers (fβ-hCG, thCG and PlGF) the difference is more 
pronounced later on (after 11 weeks) (Kuc et al., 2010). Based on this knowledge, it would be 
useful to draw two separate blood samples (a so-called two-sample combined test) to 
increase the DR of first-trimester screening to almost 90% at a 5% FPR, which is obviously a 
tremendous improvement compared to the DR of the current screening program (table 2b). 
On the other hand, adding new markers to the screening test and taking an extra blood 
sample bears extra costs and complicates the logistic process of first-trimester screening. A 
cost-effectiveness analysis is therefore necessary to evaluate the potential of such a two-
sample first-trimester screening setting.  
A more experimental proteomics approach was carried out by analyzing 90 different 
proteins from a pre-existing non-pregnancy-specific bead-based multiplexed immunoassay. 
By comparing the protein concentrations in a small cohort of DS and control sera, seven  
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Marker Description Function Potential
* Involved in proteolysis, adhesion, fusion and 
intracellular signalling  
* Interacts with IGF binding proteins
* Promotes differentiation and prevents apoptosis in 
trophoblasts
* Involved in trophoblast invasion and proliferation 
* Glycoprotein hormone that consists of a common α 
subunit and a unique β subunit
* Stimulates the ovaries to synthesize steroids to 
maintain pregnancy
* Involved in trophoblast differentiation and cell 
aggregation
* Member of the somatotropin/prolactin family that is 
expressed mainly in the placenta
* Plays an important role in growth control
IGF-1 Insulin-like growth factor 1 * Regulates placental growth and transport, 
trophoblast invasion and placental angiogenesis
examined
IGF-2 Insulin-like growth factor 2 * Has large effects on cell proliferation and 
differentiation 
examined
* Bind both IGF I and II
* Restrict trophoblast invasion  
IGFBP-2 Insulin-like growth factor binding protein 2 * Stimulate trophoblast cell migration and invasion  examined
IGFBP-3 Insulin-like growth factor binding protein 3 * Regulate IGF bioavailability and cell growth examined
IGFBP-4 Insulin-like growth factor binding protein 4 unknown
IGFBP-5 Insulin-like growth factor binding protein 5 unknown
IGFBP-6 Insulin-like growth factor binding protein 6 unknown
IGFBP-7 Insulin-like growth factor binding protein 7 unknown
* Involved in angiogenesis, growth and 
immunomodulation
* Regulation of foetal and uterine metabolism
* Involved in extracellular matrix degeneration in 
embryonic development, reproduction and tissue 
remodelling
* Play a role in endometrial menstrual breakdown, 
regulation of vascularization and the inflammatory 
response  
MMP-9 Matrix metallopeptidase 9 (gelatinase B) * Regulate several growth factors and cytokines unknown
* Cleaves IGFBPs
* Important regulator of IGF bioavailability and cell 
growth 
* Member of the somatotropin/prolactin family that is 
expressed mainly in the placenta  
* Plays an important role in growth control.  
* Has a key role in the control of IGF-1 levels
* Mainly involved in angiogenesis
* Has an autocrine function in regulating trophoblast 
function 
* Binds copper and zinc ions
* Responsible for catalyzing free superoxide radicals 
* Inhibits cytotrophoblast migration
* Decreases trophoblast proliferation
* Increases formation of placental giant cells
* Regulates many other growth factors
* Natural inhibitors of MMPs  
* Promote cell proliferation  
* Anti-apoptotic function  
* Suppress endothelial proliferation  
TIMP-2 Tissue inhibitor of matrix metallopeptidase 2 * Maintain tissue homeostasis  unknown
TIMP-3 Tissue inhibitor of matrix metallopeptidase 3 * Regulate platelet aggregation and recruitment  unknown
TIMP-4 Tissue inhibitor of matrix metallopeptidase 4 * Play a role in hormonal regulation and endometrial 
tissue remodelling 
unknown
* Mediates vascular permeability   
* Induces angiogenesis, vasculogenesis and 
endothelial cell proliferation   
examined
VEGF Vascular endothelial growth factor examined
TIMP-1 Tissue inhibitor of matrix metallopeptidase 1 unknown
TGF-β Transforming growth factor β 1 unknown
SOD-1 Superoxide dismutase 1 examined
PLGF Placental growth factor biomarker
PGH Placenta-specific growth hormone biomarker
PAPP-A Pregnancy-associated plasma protein A in use
examined
MMP-2 Matrix metallopeptidase 2 (gelatinase A) unknown
IGFBP-1 Insulin-like growth factor binding protein 1
Leptin Leptin
hPL Chorionic somatomammotropin hormone 1 
(placental lactogen)
biomarker
hCG Chorionic gonadotropin in use
EGF Epidermal growth factor (β-urogastrone) examined
ADAM12 ADAM metallopeptidase domain 12 biomarker
 
Table 1. Early biomarkers involved in placental development according to a literature study 
and data-mining. Potential for DS screening is indicated as follows: In use, currently widely 
used in DS screening; Biomarker, studies showed overall significant concentrations; 
Examined, examined as biomarker but not significant or inconclusive overall results. 
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A
5% 3% 1%
77 71 59
77 72 60
77 71 60
77 71 60
78 73 61
80 74 63
79 74 62
79 73 62
B
1
st
 (8-10 wks) 2
nd
 (11-13 wks) 5% 3% 1%
PAPP-A fβ-hCG 83 79 68
  + ADAM12 84 80 69
  + thCG 85 80 70
  + PP13   84 79 69
  + PlGF 85 80 69
  + ADAM12 & PP13   + thCG & PlGF 89 85 75
  + ADAM12   + thCG & PLGF 88 84 74
  + ADAM12   + PlGF 85 81 70
   + ADAM12, thCG & PlGF
   + ADAM12 & PlGF
One-sample test
(8-13 wks)
Two-sample test DR at FPR
DR at FPR
PAPP-A & fβ-hCG 
   + ADAM12
   + thCG
   + PP13
   + PlGF
   + ADAM12, thCG, PP13 & PlGF 
 
Table 2. Modeled detection rates (DR) at given false positive rates (FPR) for NT at 11-13 
weeks and several serum marker combinations in a one-sample (A) or two-sample test  (B). 
Models containing all markers are displayed in bold. 
potential screening markers were identified (Koster et al., 2009a): alpha fetoprotein (AFP), 
epidermal growth factor (EGF), extracellular rage binding protein (EN-RAGE), eotaxin, 
haptoglobin (HP), insulin (INS) and lipoprotein A (LPA). None of the identified proteins is 
linked to genes located on chromosome 21. However, some of the markers are known to be 
highly expressed in the placenta or foetal liver and were also proposed in the candidate 
biomarker lists from the previously described discovery studies. Unfortunately, none of the 
seven identified single markers showed significant differences between cases and controls. It 
might be that biomarkers with large distinctive power were not present on the 
immunoassay or, alternatively, that fold changes are inherently not high in maternal blood. 
Interestingly, the addition of the whole panel of seven biomarkers to the current screening 
test provided a significant improvement of the detection rate for DS. 
Despite these promising results, it is obvious that test performance is always better when a 
screening test is applied to the same cases from which the markers are derived and therefore 
application of the proposed markers on a different cohort of cases is essential to establish the  
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Fig. 2. Boxplots showing the distinction between Down syndrome cases (grey) and the 
controls (white) by plotting the median, quartiles and minimum/maximum values. (A) 
Difference between cases and controls when the three current screening markers (PAPP-A, 
fβ-hCG and NT) are used, (B) Difference between cases and controls when the current three 
screening markers are combined with the seven newly identified potential biomarkers (AFP, 
EGF, EN-RAGE, Eotaxin, HP, INS and LPA). Values along the vertical axis indicate 
prediction scores expressed as arbitrary units. 
true diagnostic accuracy of the immunoassay. This was done in a subsequent validation 
study in which 34 DS cases and matching controls were included to confirm the predictive 
value of the seven markers found in the discovery study. EGF and EN-RAGE were 
confirmed to be potential screening markers for DS and improved the DR of the current 
first-trimester combined test with approximately 6% (table 3) (Koster et al., 2010b). This may 
seem rather disappointing considering the initial identification of seven potential markers. 
On the other hand, the finding that two markers again improved the DS screening 
performance in an independent study is highly encouraging. Clearly, large scale validation 
experiments need to be performed to provide sufficient evidence for potential markers 
before they can be implemented in a screening test.  
4. Screening for Down syndrome using cell-free foetal DNA/RNA in maternal 
blood 
Currently, not only knowledge to do in-depth evaluations based on proteomic techniques is 
available, but more and more research focuses on the genomic detection of DS in maternal  
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markers in the model
discovery fit + 
discovery data
discovery fit + 
validation data
validation fit + 
discovery data
validation fit + 
validation data
current screening (PAPP-A, fβ-hCG, NT) 56.2 65.2 39.7 64.0
PAPP-A+ fβ-hCG 38.9 57.1 32.7 57.6
current+AFP 58.9 64.1 40.6 64.0
current+EGF 62.6 67.1 51.7 68.0
current+EN-RAGE 58.7 68.4 47.7 68.1
current+Eotaxin 61.1 55.8 40.7 63.8
current+Haptoglobin 61.8 62.3 36.1 64.2
current+Insulin 59.7 65.2 37.4 63.7
current+LPA 61.0 65.0 51.6 63.4
10 markers (current + 7 new) 82.5 42.4 59.2 71.5
current+EGF+EN-RAGE 62.1 70.1 53.8 71.4
DR at a 5% FPR
 
Table 3. Modeled detection rates (DR) at a given 5% false positive rate (FPR) for several 
marker combinations. Models were fitted based on the data of the discovery study or based 
on the validation study and tested on both datasets. DRs displayed in bold indicate an 
improvement compared to the current screening model. 
blood. We feel therefore that we should devote a paragraph on the potential value of this 
technique and its possible role within the screening process. One line of research concerning 
DS screening tries to put high-end sequencing quantification techniques for DNA and RNA 
into use to quantify foetal DNA or RNA, either in nuclei of foetal cells or free-floating in 
maternal serum (Lo, 2000). Non-invasive foetal genotyping became feasible when, foetal 
DNA was found to constitute approximately 10% of the DNA circulating in the mother's 
plasma (Lo et al., 1998). However, determination of the maternally inherited alleles was a 
considerable challenge because the foetal contribution to the plasma DNA can only result in 
subtle shifts to the total allelic balance, rather than providing a novel allele. 
Currently, the most promising technique is so-called massive parallel genomic sequencing. 
This technique can identify and quantify many DNA fragments in a relatively short time 
span (Chiu et al., 2008, Fan et al., 2008). Recently, a large-scale study in a high risk cohort 
was conducted to investigate the performance of massive parallel genomic sequencing in 
terms of detection and false positive rates. In this study, all DS pregnancies could be 
identified at a 2.1% false positive rate (Chiu et al., 2011). The authors claim that if such a test 
would be carried out in all women who initially had a high risk pregnancy (based on first 
trimester screening), only very few women would need a referral for an invasive diagnostic 
procedure such as amniocentesis.  However, it is unclear how the test would perform in a 
more representative low-risk pregnant population. 
With this promising non-invasive technique, it seems possible to provide definite 
identification of DS. However, there are still limitations to the technique and some reputable 
experts in the field have expressed doubts concerning these developments (Community 
Corner Nature Medicine, 2011). This line of research has been going on for over ten years 
now; the major technical challenges of sequencing foetal DNA from maternal blood may 
have been largely solved, but now the practical issues raised by applying this technology 
need to be addressed. For a diagnostic test, a false positive rate of 2.1% is unacceptable, since 
it would lead to termination of pregnancy in an equal percentage unaffected pregnancies. 
For a screening test on the other hand, the technique is still too expensive and time-
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consuming. And furthermore, if this technique keeps evolving it might even become 
possible to prenatally offer whole genome sequencing, which obviously raises a complex set 
of social and ethical issues.  
So we feel that, although it is likely that, somewhere in the near future, massive parallel 
genomic sequencing will be used as an intermediate step in the prenatal detection of DS to 
decrease the number of invasive procedures such as amniocentesis, the technique is still a 
long way from implementation in a high-throughput screening setting. 
5. Future perspectives and ongoing research 
The research described in this chapter focuses on the directive search for new markers for 
DS using the ever expanding knowledge of the human genome and proteome and combines 
both laboratory techniques and digital evaluation of data (data mining). The current first 
trimester combined test is based on enzyme-linked immunosorbent assay (ELISA) methods, 
which is widely used for quantitative protein measurements. Recently, two-dimensional gel 
electrophoresis (2-D), tandem mass spectrometry (MS-MS) and bead-based multiplexed 
immunoassays have been used to identify several potential biomarkers in amniotic fluid and 
maternal blood (Busch et al., 2005, Kolialexi et al., 2008, Nagalla et al., 2007, Tsangaris et al., 
2006), clearly demonstrating the potential of applying proteomics techniques in the quest for 
new biomarkers. Bead-based multiplexed immunoassays use color-coded tiny beads in up 
to 100 distinct sets. Coating each bead set with a specific reagent allows the capture and 
detection of many specific analytes, such as proteins, from a sample. Next, labeled beads are 
incubated with serum samples and, subsequently, with a detection antibody labeled with a 
reporter dye in a bead-based immunoassay. Flow cytometry equipment measures the 
internal dyes to identify each particle and the reporter dye captured during the assay 
(Krishhan et al., 2009). Another proteomics technique is the use of Antibody microarrays 
(Ab-arrays). Ab-arrays are a platform for protein expression profiling. Small amounts of 
capture antibodies for the selected targets are immobilized or spotted on a very small area 
on coated glass slides. The high density of the capture antibodies in the spots that is 
obtained enables high sensitivity (Ekins, 1989). These technologies allow analyzing many 
unique markers within a single sample, both rapidly and precisely, in a high-throughput 
setting. In the boost of new development the question arises whether these advanced 
detection techniques will be available at a reasonable cost, a prerequisite for screening tests. 
In principle however, Ab-array techniques are calculated to cost within the range of 20-50 
Euros per screening. 
In recent years, the focus of prenatal screening has expanded. Several studies have been 
performed to evaluate the potential of prenatal screening for foetal chromosomal 
abnormalities other than DS, in particular Edwards syndrome (trisomy 18) and Patau 
syndrome (trisomy 13). With the first-trimester combined test it is possible to detect these 
trisomies using the same algorithm as for DS screening (Spencer et al., 2000, Tul et al., 1999). 
In trisomy 18 and 13 pregnancies PAPP-A levels are decreased to a greater extent than in DS 
and the NT is often very large. However, as opposed to DS, serum concentrations of fβ-hCG 
are decreased in trisomy 18 and 13 pregnancies. Thus, with a slight adjustment of the DS 
risk calculation, it would be possible to provide separate risks specifically for trisomy 18 and 
13. This would lead to the detection of many trisomy 18 and 13 cases with only 0.2% extra 
false positives (Koster et al., 2010c).  
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This spin-off of the current proteomics project may have opened a completely new field of 
research. Currently, a similar approach has been set up to identify potential screening 
markers for pregnancy complications such as pre-eclampsia (PE), intrauterine growth 
restriction and foetal death. PE is a serious complication of pregnancy that affects 
approximately 1-2% of all pregnant women and it is the leading cause of maternal and 
perinatal morbidity and mortality (Gaugler-Senden et al., 2006). Because of the serious 
health consequences of PE, risk assessment for PE is highly recommended. Early 
identification of women at risk might facilitate better antenatal surveillance, timely 
intervention and better outcomes.  
Especially new proteomic techniques will need only minute amounts of test material; 10-20 
micro-litres serum instead of 1-2 ml. Hypothetically, this downscaling opens the possibility 
to draw small amounts of blood and to replace the relatively laborious venous puncture 
with a finger prick. Our first studies comparing venous blood with capillary blood (derived 
from a finger prick), drawn at the same time from pregnant women, indeed show that 
capillary blood can be reliably used to determine the currently used biomarkers in serum. 
The laboratory will be able to analyze a combination of approximately ten markers. Based 
on these developments, it must surely be possible to detect, in the same samples, all 
parameters of prenatal screening (e.g. irregular blood types and infectious diseases, like HIV 
and hepatitis) and to identify high risks for foetal (e.g. chromosomal abnormalities) and 
maternal (e.g. pre-eclampsia) pregnancy complications. 
In the next coming years, the outline of such a future prenatal screening is feasible, however; 
it will probably take some time before these methods can be tested in large cohorts that 
proof their efficacy as a screening tool, a bare necessity before actual implementation can 
take place.  
6. Conclusion 
It is anticipated that the introduction of a new screening method consists of a discovery 
phase, taking 1-3 years, a validation phase, taking 2-5 years, and an implementation phase, 
taking 5-7 years. This means that of all of the discoveries presented in this paper, which are 
clearly done in the realm of the discovery phase, very few will make it to becoming an 
element of an implemented screening test. While we cannot predict what the prenatal 
screening test for Down syndrome, other aneuplodies and foetal and maternal health will be 
in ten years time, we can state that it will not be the first trimester combined test. The past 
decades have learned sufficiently that the screening tests, while not being volatile, are liable 
to changes, and this will not stop in the next years. It is safe to say that the future test will 
use the complete array of proteomics, genomics and ultrasound markers, to provide a 
continuum of tests, with the sole purpose of improving in general the outcome of 
pregnancies, including the health perspective of the mother, worldwide.  
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